INOInovio Pharmaceuticals Inc
INO
Inovio Pharmaceuticals Inc92,460
Mkt Cap
$115.18MVolume
3.41M52W High
$5.2652W Low
$1.30PE Ratio
-0.77INO Fundamentals
Price
$2.00Prev Close
$2.15Open
$2.0050D MA
$2.43Beta
1.38Avg. Volume
1.02MEPS (Annual)
-$3.95P/B
-13.88Rev/Employee
$1,625.05Poll
Earnings Recap
In Q3 2025, Inovio reported a net loss of $45.5 million (or $0.87 per share) driven by warrant liability adjustments and expects file acceptance by the FDA by year end for INO-3107 with a potential PDUFA date in mid-2026.
Bullish
Completed the rolling submission of their BLA for INO-3107 and expect to receive file acceptance by the FDA by year end, and they have requested a priority review of the BLA, which, if granted, would provide for a potential PDUFA date around mid 2026.
Bearish
Cash runway is estimated to take them into the second quarter of 2026, and this projection includes a net operational cash burn estimate of approximately $22 million for the fourth quarter of 2025.